Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21050265 | 1.00 | HTR2B (0.36) | HTR2BADORA3ADORA1HDAC1HDAC2 | |
| SCHEMBL21050259 | 0.90 | ADORA3 (0.36) | HTR2BADORA3ADORA1 | |
| SCHEMBL21050222 | 0.90 | ADORA3 (0.36) | HTR2BADORA3ADORA1 | |
| SCHEMBL21050241 | 0.84 | HTR2B (0.32) | HTR2B | |
| SCHEMBL21100584 | 0.83 | HTR2B (0.31) | HTR2B | |
| SCHEMBL21100304 | 0.81 | HTR2B (0.38) | HTR2BADORA3ADORA1 | |
| SCHEMBL21050237 | 0.81 | LMNA (0.45) | HTR2BADORA3ADORA1 | |
| SCHEMBL21050319 | 0.81 | LMNA (0.45) | HTR2BADORA3ADORA1 | |
| Phosphoric Acid SCHEMBL21050308 | 0.79 | HTR2B (0.30) | HTR2B | |
| Phosphoric Acid SCHEMBL21050225 | 0.79 | HTR2B (0.30) | HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040975-B2 | Carbocyclic nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-06-22 | — | — | US | claimed |
| US-20190177326-A1 | CARBOCYCLIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-06-13 | — | — | US | claimed |
| US-11040975-B2 | Carbocyclic nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-06-22 | — | — | US | disclosed |
| US-11040975-B2 | Carbocyclic nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20190177326-A1 | CARBOCYCLIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-06-13 | — | — | US | disclosed |
| US-20190177326-A1 | CARBOCYCLIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040975-B2 | Carbocyclic nucleoside reverse transcriptase inhibitors | SAMHD1, POLRMT, RNGTT | HTR2B 3381/4885ADORA3 712/4885ADORA1 616/4885 |
| US-20190177326-A1 | CARBOCYCLIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | SAMHD1, POLRMT, RNGTT | HTR2B 3381/4885ADORA3 712/4885ADORA1 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.